{"id":124991,"date":"2026-11-19T14:35:57","date_gmt":"2026-11-19T13:35:57","guid":{"rendered":"https:\/\/www.aplusaresearch.com\/?p=124991"},"modified":"2026-11-19T14:38:22","modified_gmt":"2026-11-19T13:38:22","slug":"biomarkers-molecular-tumor-boards-and-ai-in-oncology","status":"publish","type":"post","link":"https:\/\/www.aplusaresearch.com\/fr\/perspectives\/biomarkers-molecular-tumor-boards-and-ai-in-oncology\/","title":{"rendered":"Biomarqueurs, RCP mol\u00e9culaires et IA en oncologie"},"content":{"rendered":"<h2 class=\"wp-block-heading\">Comment transformer les donn\u00e9es mol\u00e9culaires en d\u00e9cisions cliniques, et quelles sont les implications pour la strat\u00e9gie pharmaceutique ?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Disponible en fran\u00e7ais et en anglais, ce podcast APLUSA rassemble les enseignements cl\u00e9s de notre <a href=\"https:\/\/www.aplusaresearch.com\/fr\/events\/briefings\/2026\/oncology-breakfast-briefing-2026\/\" data-type=\"events\" data-id=\"60323\" target=\"_blank\" rel=\"noopener\">Matinale de l'Oncologie<\/a>, au cours de laquelle des oncologues, pathologistes et biologistes mol\u00e9culaires exer\u00e7ant en France ont partag\u00e9 leurs perspectives.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">En moins de cinq minutes, d\u00e9couvrez le r\u00f4le des RCP mol\u00e9culaires, les freins \u00e0 l\u2019acc\u00e8s aux tests et aux traitements, ainsi que les opportunit\u00e9s et les conditions d\u2019adoption de l\u2019IA en pathologie. Cet \u00e9pisode met ces \u00e9changes en perspective avec les enjeux des laboratoires pharmaceutiques : comprendre les parcours li\u00e9s aux biomarqueurs et identifier les \u00e9carts entre potentiel scientifique et pratiques en vie r\u00e9elle.<\/p>\n\n\n\n<figure class=\"wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio\"><div class=\"wp-block-embed__wrapper\">\n<iframe loading=\"lazy\" hcb-fetch-image-from=\"https:\/\/www.youtube.com\/watch?v=EPGlxjpyCzM\" title=\"Oncologie de pr\u00e9cision : biomarqueurs, RCP mol\u00e9culaires et IA | Podcast APLUSA\" width=\"500\" height=\"281\" src=\"https:\/\/www.youtube.com\/embed\/EPGlxjpyCzM?feature=oembed\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe>\n<\/div><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">Pour approfondir ces sujets, consultez notre article compl\u00e9mentaire, <a href=\"https:\/\/www.aplusaresearch.com\/fr\/perspectives\/biomarkers-molecular-tumor-boards-and-ai-how-is-oncology-decision-making-evolving\/\" data-type=\"post\" data-id=\"119458\" target=\"_blank\" rel=\"noopener\">Biomarqueurs, RCP mol\u00e9culaires et IA : comment la prise de d\u00e9cision \u00e9volue-t-elle en oncologie ?<\/a>, qui explore plus en d\u00e9tail les \u00e9changes et leurs implications.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Retrouvez d\u2019autres \u00e9changes et \u00e9clairages dans la <a href=\"https:\/\/www.youtube.com\/playlist?list=PLf5IOYgkAWIs\" target=\"_blank\" rel=\"noopener\">playlist APLUSA Podcast<\/a>, dont la version anglaise de cet \u00e9pisode, et abonnez-vous \u00e0 notre cha\u00eene YouTube pour d\u00e9couvrir les prochains \u00e9pisodes.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>","protected":false},"excerpt":{"rendered":"<p>What does it take to turn molecular insights into clinical decisions and what does this mean for pharmaceutical strategy? Available in English and French, this APLUSA podcast brings together key insights from our Oncology Breakfast Briefing, where oncologists, pathologists and molecular biologists practicing in France shared their perspectives. In under five minutes, explore the role [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":125001,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"content-type":"","footnotes":""},"categories":[108],"tags":[],"expertise":[107],"class_list":["post-124991","post","type-post","status-publish","format-standard","has-post-thumbnail","category-podcasts","expertise-oncology"],"acf":[],"permalink_manager":null,"_links":{"self":[{"href":"https:\/\/www.aplusaresearch.com\/fr\/wp-json\/wp\/v2\/posts\/124991","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.aplusaresearch.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.aplusaresearch.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.aplusaresearch.com\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.aplusaresearch.com\/fr\/wp-json\/wp\/v2\/comments?post=124991"}],"version-history":[{"count":3,"href":"https:\/\/www.aplusaresearch.com\/fr\/wp-json\/wp\/v2\/posts\/124991\/revisions"}],"predecessor-version":[{"id":125004,"href":"https:\/\/www.aplusaresearch.com\/fr\/wp-json\/wp\/v2\/posts\/124991\/revisions\/125004"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.aplusaresearch.com\/fr\/wp-json\/wp\/v2\/media\/125001"}],"wp:attachment":[{"href":"https:\/\/www.aplusaresearch.com\/fr\/wp-json\/wp\/v2\/media?parent=124991"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.aplusaresearch.com\/fr\/wp-json\/wp\/v2\/categories?post=124991"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.aplusaresearch.com\/fr\/wp-json\/wp\/v2\/tags?post=124991"},{"taxonomy":"expertise","embeddable":true,"href":"https:\/\/www.aplusaresearch.com\/fr\/wp-json\/wp\/v2\/expertise?post=124991"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}